Log In
BCIQ
Print this Print this
 

SP2086/valsartan

  Manage Alerts
Collapse Summary General Information
Company Jiangsu Hengrui Medicine Co. Ltd.
DescriptionFixed-dose combination of 100 mg SP2086 and 80 mg valsartan
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26) ; Angiotensin II type 1 (AT1) receptor (AGTR1)
Mechanism of ActionDipeptidyl peptidase-4 (DPP-4) inhibitor; Angiotensin II type 1 (AT1) receptor (ATGR1) antagonist
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase I
Standard IndicationDiabetes
Indication DetailsTreat type II diabetes
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today